Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.
Drug-membrane interactions of the candesartan cilexetil (TCV-116) have been studied on molecular basis by applying various complementary biophysical techniques namely differential scanning calorimetry (DSC), Raman spectroscopy, small and wide angle X-ray scattering (SAXS and WAXS), solution ¹H and ¹³C nuclear magnetic resonance (NMR) and solid state ¹³C and ³¹P (NMR) spectroscopies. In addition, ³¹P cross polarization (CP) NMR broadline fitting methodology in combination with ab initio computations has been applied. Finally molecular dynamics (MD) was applied to find the low energy conformation and position of candesartan cilexetil in the bilayers. Thus, the experimental results complemented with in silico MD results provided information on the localization, orientation, and dynamic properties of TCV-116 in the lipidic environment. The effects of this prodrug have been compared with other AT₁ receptor antagonists hitherto studied. The prodrug TCV-116 as other sartans has been found to be accommodated in the polar/apolar interface of the bilayer. In particular, it anchors in the mesophase region of the lipid bilayers with the tetrazole group oriented toward the polar headgroup spanning from water interface toward the mesophase and upper segment of the hydrophobic region. In spite of their localization identity, their thermal and dynamic effects are distinct pointing out that each sartan has its own fingerprint of action in the membrane bilayer, which is determined by the parameters derived from the above mentioned biophysical techniques.
Chemistry Department, National and Kapodistrian University of Athens, Panepistimioupolis Zographou 15771, Greece.
Charalambos
C
Fotakis
Grigorios
G
Megariotis
Dionysios
D
Christodouleas
Eftichia
E
Kritsi
Panagiotis
P
Zoumpoulakis
Dimitrios
D
Ntountaniotis
Maria
M
Zervou
Constantinos
C
Potamitis
Aden
A
Hodzic
Georg
G
Pabst
Michael
M
Rappolt
Gregor
G
Mali
Johanna
J
Baldus
Clemens
C
Glaubitz
Manthos G
MG
Papadopoulos
Antreas
A
Afantitis
Georgia
G
Melagraki
Thomas
T
Mavromoustakos
D047228:Angiotensin II Type 1 Receptor Blockers / Q000378:metabolism*; D001562:Benzimidazoles / Q000737:chemistry / Q000378:metabolism*; D001713:Biphenyl Compounds / Q000737:chemistry / Q000378:metabolism*; D002462:Cell Membrane / Q000187:drug effects* / Q000378:metabolism; D007093:Imidazoles / Q000737:chemistry / Q000378:metabolism; D008051:Lipid Bilayers / Q000378:metabolism*; D008968:Molecular Conformation; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D013777:Tetrazoles / Q000737:chemistry / Q000378:metabolism*; D013816:Thermodynamics; D014633:Valine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007093:Imidazoles; D008051:Lipid Bilayers; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D000068756:Valsartan; C437965:olmesartan; D014633:Valine; C077793:candesartan cilexetil; C081643:candesartan